Julia Bershadsky

Julia Bershadsky is a Senior Scientist at Notch Therapeutics, specializing in cell line development since January 2021. Key responsibilities include developing strategies for gene editing technologies and leading multidisciplinary teams in generating engineered iPSC lines. Previous roles include Scientist II at Notch Therapeutics, where Julia established the clinical manufacturing process for engineered clonal iPSC lines, and Research Scientist at Endogena Therapeutics, where Julia advanced drug discovery for degenerative diseases. Julia's postdoctoral work at Trillium Therapeutics focused on elucidating the mechanism of action for a CD47-blocking innate immune checkpoint inhibitor, resulting in significant scientific contributions and presentations. Julia's foundational experience includes research associate work at University Health Network and teaching assistance at the University of Toronto. Julia holds a Ph.D. in Notch Regulation in Breast Cancer from the University of Toronto and a B.Sc. with honors in Biochemistry from York University.